Mabqi

Executive Summary

Mabqi is a Paris-based biotech company founded in 2017 that leverages proprietary fully human synthetic antibody libraries combined with AI-powered phage and yeast display technologies. The company's platform aims to discover next-generation antibodies with high developability and functionality, addressing key challenges in antibody drug discovery such as immunogenicity and off-target effects. By integrating artificial intelligence into library design and selection, Mabqi seeks to expedite the identification of lead candidates with optimized properties, potentially improving success rates in preclinical and clinical development. While Mabqi's technology holds promise, the company remains in early stages with no disclosed pipeline or publicly available data on partnerships or funding. Its competitive advantage hinges on validating the platform's ability to generate superior antibodies relative to existing methods. The absence of disclosed catalysts suggests the company is still building its foundation; however, successful platform validation or strategic collaborations could unlock significant value. Mabqi's focus on fully human antibodies positions it well in the growing antibody therapeutics market, though near-term visibility is limited.

Upcoming Catalysts (preview)

• Q3 2026Publication of Platform Validation Data45% success
• Q4 2026Strategic Partnership with Pharmaceutical Company30% success
• H2 2026Series B Financing Round35% success